Polycystic Ovarian Syndrome (PCOS)NCT07711782
Management of Polycystic Ovarian Syndrome-associated Reproductive Dysfunction Through Kefir Supplementation
A study testing (G1) Experimental group in people with Polycystic Ovarian Syndrome (PCOS) and Reproductive Health, run by University of Lahore at 1 site in Pakistan.
Trial summary
Polycystic ovary syndrome (PCOS) affect around 6-12% of women of age 18-25 years. Kefir contains bioactive compounds such as lactic acid bacteria, yeast, peptides, polysaccharides and organic acids and acts as a good probiotic source. Read more about this study
- Who is it for?
- Ages 18 to 25 years, women only
- Conditions the study is for
- Polycystic Ovarian Syndrome (PCOS), Reproductive Health
- What is being tested?
- (G1) Experimental group
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 sitePakistan
- Study dates
- 18 Jan 2026to 18 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 25 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Females of age 18-25 will be selected.
- Females suffering from amenorrhea or cycle longer then 35days were selected.
- Females with PCOS were selected.
- Females with BMI 18.5-29.9 were selected in this research.
- Females with thyroid issues were selected.
Who cannot join
- Pregnant and breast-feeding females were not included.
- Those who smoke were not included.
- Those who consume alcohol were not included.
- Those suffering from endocrine diseases were not be included.
- Those taking lipid- lowering drugs or blood pressure regulating medications were not be included.
- Those taking antibiotics or medications related to PCOS treatment or vitamin-mineral or probiotics within 1 month prior to study inclusion.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Managing Polycystic Ovarian Syndrome- Associated Reproductive Dysfunction Through Kefir Supplementation
Polycystic ovary syndrome (PCOS) affect around 6-12% of women of age 18-25 years. Kefir contains bioactive compounds such as lactic acid bacteria, yeast, peptides, polysaccharides and organic acids and acts as a good probiotic source.
Read the detailed description
The target population were females between the ages of 18 and 25 years who have the history of amenorrhea or delayed periods, unusual weight gain, cyst in their ovaries, hormonal imbalance or thyroid issue. Once consent is given, participants were then be randomly assigned to receive the prescribed intervention or act as a control.
(C0) Control group: Participants were only be subjected to use a regular calorie deficit diet plan (G1) Experimental group: Participants were advised to take water 250ml of water kefir per day in their mid-morning snack time for 2 months.
At baseline, nutritional assessment based on weight and height, BMI, waist circumference, blood pressure, fasting blood glucose, lipid panels (HDL, LDL, total cholesterol, triglycerides), FHS Levels, LH levels, TSH levels was done after 8 weeks of intervention.
- Being tested
- (C0) Control group, (G1) Experimental group
- Keywords
- Kefir water, poly cystic ovarian syndrome, reproductive health
- Medical subject headings
- Polycystic Ovary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
(C0) Control groupOther
Participants were subjected to use a regular calorie deficit diet plan
(G1) Experimental groupDietary supplement
Participants were advised to take water 250ml of water kefir per day in their mid-morning snack time for 2 months.
| Study group | Role | What they receive |
|---|---|---|
| Control Group | Active comparator | Calorie deficit diet plan Receives: Other: (C0) Control group |
| Experimental Group | Experimental | Diet plan + 250ml kefir water Receives: Dietary Supplement: (G1) Experimental group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lipid Profile
Blood lipid profile were obtained using fasting blood samples to determine serum total cholesterol, high-density lipoprotein cholesterol (HD L-C), low density lipoprotein cholesterol (LDL-C) and triglycerides.
Measured: 8 weeks
Secondary outcomes (2)
FSH (follicle stimulating hormone)
Blood test will be done to check the reproductive health
Measured: 8 weeks
LH (luteinizing hormone)
Blood test to check the secretion of luteinizing hormone and how it triggers ovulation and stimulate testosterone production.
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2026
- Study start18 Jan 2026
- Primary completion18 Mar 2026
- Study completion18 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Polycystic Ovarian Syndrome (PCOS)Studies of the same condition, open and under way.
- More trials run by University of LahoreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Lahore
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Maria Aslam, University of Lahore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07711782
- Sponsor's protocol ID
- IRB-UOL-FAHS/761/2026
- Status last verified
- Jul 2026
- First submitted
- 13 Jul 2026
- Last updated
- 17 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Managing Polycystic Ovarian Syndrome- Associated Reproductive Dysfunction Through Kefir Supplementation
- ClinicalTrials.gov ID
- NCT07711782
- Acronym / sponsor ID
- IRB-UOL-FAHS/761/2026
- Keywords
- Kefir water, poly cystic ovarian syndrome, reproductive health
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- University of LahoreUniversity, hospital or other
- Study start
- 18 Jan 2026 (actual)
- Primary completion
- 18 Mar 2026 (actual)
- Study completion
- 18 Apr 2026 (actual)
- First posted
- 17 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Polycystic ovary syndrome (PCOS) affect around 6-12% of women of age 18-25 years. Kefir contains bioactive compounds such as lactic acid bacteria, yeast, peptides, polysaccharides and organic acids and acts as a good probiotic source.
Detailed description
The target population were females between the ages of 18 and 25 years who have the history of amenorrhea or delayed periods, unusual weight gain, cyst in their ovaries, hormonal imbalance or thyroid issue. Once consent is given, participants were then be randomly assigned to receive the prescribed intervention or act as a control.
(C0) Control group: Participants were only be subjected to use a regular calorie deficit diet plan (G1) Experimental group: Participants were advised to take water 250ml of water kefir per day in their mid-morning snack time for 2 months.
At baseline, nutritional assessment based on weight and height, BMI, waist circumference, blood pressure, fasting blood glucose, lipid panels (HDL, LDL, total cholesterol, triglycerides), FHS Levels, LH levels, TSH levels was done after 8 weeks of intervention.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control Group | Active comparator | Other: (C0) Control groupCalorie deficit diet plan |
| Experimental Group | Experimental | Dietary Supplement: (G1) Experimental groupDiet plan + 250ml kefir water |
Who may qualify
- Ages
- 18 to 25 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Females of age 18-25 will be selected.
- Females suffering from amenorrhea or cycle longer then 35days were selected.
- Females with PCOS were selected.
- Females with BMI 18.5-29.9 were selected in this research.
- Females with thyroid issues were selected.
Key exclusion criteria (6 listed)
- Pregnant and breast-feeding females were not included.
- Those who smoke were not included.
- Those who consume alcohol were not included.
- Those suffering from endocrine diseases were not be included.
- Those taking lipid- lowering drugs or blood pressure regulating medications were not be included.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| (C0) Control groupParticipants were subjected to use a regular calorie deficit diet plan | Other | Control Group |
| (G1) Experimental groupParticipants were advised to take water 250ml of water kefir per day in their mid-morning snack time for 2 months. | Dietary supplement | Experimental Group |
Primary outcome
Lipid Profile
Time frame: 8 weeks
Blood lipid profile were obtained using fasting blood samples to determine serum total cholesterol, high-density lipoprotein cholesterol (HD L-C), low density lipoprotein cholesterol (LDL-C) and triglycerides.
2 secondary outcomes
FSH (follicle stimulating hormone)
Time frame: 8 weeks
LH (luteinizing hormone)
Time frame: 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Yes
Related trials for Polycystic Ovarian Syndrome (PCOS)
Recruiting
Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS
PCOS (Polycystic Ovary Syndrome)
RecruitingPhase 1
Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome
Anovulatory Infertility
RecruitingObservational study
The Value of LC-MS/MS Detection of Androgen Profiles in the Diagnosis of PCOS: A Prospective, Multicenter Real-world Study
Polycystic Ovary Syndrome (PCOS)
Recruiting
The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome
PCOS (Polycystic Ovary Syndrome)
Recruiting
Brown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography
Polycystic Ovary Syndrome (PCOS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing (G1) Experimental group in people with Polycystic Ovarian Syndrome (PCOS) and Reproductive Health, run by University of Lahore at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lipid Profile (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.